Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
10.39
+0.55 (5.59%)
At close: Oct 20, 2025, 4:00 PM EDT
10.53
+0.14 (1.35%)
After-hours: Oct 20, 2025, 7:59 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $7.89M in the quarter ending August 31, 2025, a decrease of -37.29%. This brings the company's revenue in the last twelve months to $83.69M, up 48.32% year-over-year. In the fiscal year ending November 30, 2024, Nurix Therapeutics had annual revenue of $54.55M, down -29.15%.
Revenue (ttm)
$83.69M
Revenue Growth
+48.32%
P/S Ratio
9.70
Revenue / Employee
$292,612
Employees
286
Market Cap
798.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NRIX News
- 2 days ago - Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire
- 9 days ago - Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones - Seeking Alpha
- 11 days ago - Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 5 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 5 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 5 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha